HC Wainwright Boosts Earnings Estimates for Spyglass Pharma

Spyglass Pharma, Inc. (NASDAQ:SGP) – Equities researchers at HC Wainwright raised their Q2 2026 EPS estimates for shares of Spyglass Pharma in a note issued to investors on Friday, May 29th. HC Wainwright analyst Y. Chen now forecasts that the company will earn ($0.46) per share for the quarter, up from their prior forecast of ($0.47). HC Wainwright currently has a “Buy” rating and a $37.00 target price on the stock. HC Wainwright also issued estimates for Spyglass Pharma’s Q3 2026 earnings at ($0.50) EPS, Q4 2026 earnings at ($0.50) EPS, FY2026 earnings at ($2.08) EPS and FY2027 earnings at ($2.14) EPS.

Several other brokerages have also recently issued reports on SGP. Citigroup began coverage on shares of Spyglass Pharma in a report on Tuesday, March 3rd. They issued a “buy” rating and a $42.00 target price for the company. Stifel Nicolaus began coverage on shares of Spyglass Pharma in a report on Tuesday, March 3rd. They issued a “buy” rating and a $42.00 target price for the company. Wall Street Zen downgraded shares of Spyglass Pharma from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. Leerink Partners downgraded Spyglass Pharma to a “market perform” rating in a research note on Tuesday, March 3rd. Finally, Zacks Research raised shares of Spyglass Pharma to a “hold” rating in a report on Wednesday, March 4th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Spyglass Pharma currently has an average rating of “Moderate Buy” and a consensus target price of $45.00.

Spyglass Pharma Trading Down 4.9%

NASDAQ:SGP opened at $18.32 on Tuesday. Spyglass Pharma has a 1-year low of $18.18 and a 1-year high of $32.44. The stock has a 50-day simple moving average of $23.12.

Spyglass Pharma (NASDAQ:SGP) last released its earnings results on Thursday, May 14th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.02).

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of SGP. The Manufacturers Life Insurance Company bought a new position in Spyglass Pharma during the first quarter valued at $308,000. Bank of America Corp DE bought a new position in Spyglass Pharma during the first quarter valued at $726,000. Monashee Investment Management LLC bought a new position in Spyglass Pharma during the first quarter valued at $2,461,000. Affinity Asset Advisors LLC bought a new position in Spyglass Pharma during the first quarter valued at $6,478,000. Finally, First Light Asset Management LLC bought a new position in Spyglass Pharma during the first quarter valued at $9,716,000.

About Spyglass Pharma

We are a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. Our mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation. Our lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), comprising novel, proprietary drug pads attached to our intraocular lens (IOL), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma (OAG) or ocular hypertension (OHT).